Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Share-based Compensation (2021 - 2025)

Lucid Diagnostics (LUCD) has disclosed Share-based Compensation for 5 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation fell 30.34% year-over-year to $1.1 million, compared with a TTM value of $4.0 million through Sep 2025, up 23.91%, and an annual FY2024 reading of $4.2 million, down 27.4% over the prior year.
  • Share-based Compensation was $1.1 million for Q3 2025 at Lucid Diagnostics, down from $1.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $3.8 million in Q2 2022 and bottomed at -$97000.0 in Q4 2023.
  • Average Share-based Compensation over 5 years is $1.9 million, with a median of $1.5 million recorded in 2024.
  • The sharpest move saw Share-based Compensation plummeted 103.72% in 2023, then skyrocketed 945.36% in 2024.
  • Year by year, Share-based Compensation stood at $3.1 million in 2021, then dropped by 15.57% to $2.6 million in 2022, then crashed by 103.72% to -$97000.0 in 2023, then surged by 945.36% to $820000.0 in 2024, then grew by 28.54% to $1.1 million in 2025.
  • Business Quant data shows Share-based Compensation for LUCD at $1.1 million in Q3 2025, $1.1 million in Q2 2025, and $1.0 million in Q1 2025.